|Articles|April 1, 1999

Psychiatrists: more patients, more scripts

Psychiatrists saw more patients and were responsible for a greater number of prescriptions in 1998.

Psychiatrists saw more patients and were responsible for a greater number of prescriptions in 1998, according to a recent report released by Newtown, PA-based Scott-Levin.

For the 12 months ending October 1998, psychiatrists received more than 58 million visits - an increase of 4% over the year before.

As a result of those consultations, they wrote 93.1 million retail prescriptions, or 1,815 prescriptions per doctor. That's 5% more prescriptions than the number psychiatrists wrote the year before. In total, psychiatrists were responsible for $5.6 billion in retail prescription sales.

"The main fact could be that psychiatrists have had a lot more attention lately from specialty sales forces. They are receiving a lot more details, mainly due to the companies' strategies," said Andrew Diefes, a marketing research analyst for Scott-Levin, when asked why psychiatrists were writing a greater volume of prescriptions.

According to Scott-Levin, the top products prescribed by psychiatrists were the same drugs that were most detailed. Prozac accounted for 8.1% of prescriptions, Zoloft received 5.4% of prescriptions and Paxil accounted for 5% of prescriptions.

By therapeutic class, the top five classes prescribed by psychiatrists were: specific neurotransmitter modulators, such as selective serotonin receptor inhibitors and selective NR inhibitors, (24.5%); seizure disorder therapies, (10.4%); antipsychotics, (9.5%); benzodiazepines, (9.3%); and similar antidepressants, (7.5%).

Sales reps made 2.6 million details to psychiatrists for the year ended October 1998, making psychiatrists the fifth most detailed group of doctors. PR


Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.